Individuals living with cystic fibrosis (CF) commonly report high symptom burden, poor quality of life, and additional psychosocial stressors; these burdens are particularly heightened in advanced stages of the disease. Although supportive care (aka palliative care) has been shown to improve many of these outcomes among patients with illnesses such as cancer, no clinical trials to date have tested the impact of supportive care for patients with CF. The purpose of this pilot randomized clinical trial study is to evaluate the feasibility, acceptability, and perceived effectiveness of an embedded supportive care intervention, whereby a supportive care specialist will be integrated within the usual care experience of patients with advanced CF. The investigators will enroll 50 patients with advanced CF, who will be equally randomized to receive this embedded supportive care intervention or usual care. Secondary measures include: patient quality of life, mood, coping style, satisfaction with care, and symptom burden. This study will provide preliminary data to support the development of a larger, definitive, Phase III randomized clinical trial.
As described above.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
50
Patients in the intervention arm of the study will see a SC specialist during regularly-scheduled CF clinic visits; per usual care, these visits should occur on a quarterly basis. Using a structured intervention manual, these visits will span 30-60 minutes each. Each visit will have a specific focus, such as: 1) comprehensive palliative care assessment; 2) symptom assessment and self-management; 3) advance care planning; and, 4) coping and resilience. Patients requiring follow up with SC before the next CF appointment will receive telephone follow up or an extra SC visit at the discretion of the SC provider.
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Feasibility of intervention
Measured by: eligibility rate, approach-to-consent rate, approach-to-enroll rate, rate of missed intervention sessions, rate of missing data on patient-reported outcomes.
Time frame: Up to 9 months (+/- 4 weeks)
Acceptability of intervention
Measured by: proportion of participants who endorse the intervention as acceptable.
Time frame: Up to 9 months (+/- 4 weeks)
Perceived effectiveness of intervention
Measured by: proportion of participants who endorse that they believe the intervention to have been beneficial.
Time frame: Up to 9 months (+/- 4 weeks)
Intervention fidelity
Evaluate the fidelity of intervention delivery using structured visit checklists to be completed by the interventionist and research staff.
Time frame: Up to 9 months (+/- 4 weeks)
Patient quality of life: Cystic Fibrosis Questionnaire-Revised (CFQ-R)
Change in QOL from baseline as measured by the Cystic Fibrosis Questionnaire-Revised (CFQ-R) at 9 months. Due to the pilot nature of this trial, this measure will not be used to assess the efficacy of the intervention.
Time frame: Up to 9 months (+/- 4 weeks)
Patient mood
Change in mood from baseline using the Hospital Anxiety and Depression Scale (HADS), reported at 0, 3, 6, 9 months. Due to the pilot nature of this trial, this measure will not be used to assess the efficacy of the intervention.
Time frame: Up to 9 months (+/- 4 weeks)
Coping style
Change in coping style from baseline using the Brief COPE, reported at 0, 3, 6, 9 months. Due to the pilot nature of this trial, this measure will not be used to assess the efficacy of the intervention.
Time frame: Up to 9 months (+/- 4 weeks)
Satisfaction with care
Change in satisfaction with care from baseline using the FAMCARE-P13, reported at 0, 3, 6, 9 months. Due to the pilot nature of this trial, this measure will not be used to assess the efficacy of the intervention.
Time frame: Up to 9 months (+/- 4 weeks)
Symptom burden
Change in symptom burden from baseline using the Edmonton Symptom Assessment Scale (ESAS), reported at 0, 3, 6, 9 months. Due to the pilot nature of this trial, this measure will not be used to assess the efficacy of the intervention.
Time frame: Up to 9 months (+/- 4 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.